Lakewood-Amedex Biotherapeutics Inc. (LABT) Stock Statistics & Valuation Metrics
Total Valuation
Lakewood-Amedex Biotherapeutics Inc. has a market cap or net worth of $473.94K. The enterprise value is ―.
- Market Cap
- $473.94K
- Enterprise Value
- ―
Share Statistics
Lakewood-Amedex Biotherapeutics Inc. has 2,369,688 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 2,369,688
- Owned by Insiders
- ―
- Owned by Institutions
- 1.89%
Financial Efficiency
Lakewood-Amedex Biotherapeutics Inc.’s return on equity (ROE) is 1.96 and return on invested capital (ROIC) is 1240.11%.
- Return on Equity (ROE)
- 1.96
- Return on Assets (ROA)
- -7.99
- Return on Invested Capital (ROIC)
- 1240.11%
- Return on Capital Employed (ROCE)
- 1.96
- Revenue Per Employee
- 0
- Profits Per Employee
- -769.53K
- Employee Count
- 5
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Lakewood-Amedex Biotherapeutics Inc. is -0.02. Lakewood-Amedex Biotherapeutics Inc.’s PEG ratio is 0.00.
- PE Ratio
- -0.02
- PS Ratio
- 0.00
- PB Ratio
- 0.07
- Price to FCF
- -0.10
- Price to Operating Cash Flow
- -0.08
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Lakewood-Amedex Biotherapeutics Inc. had revenue of 0 and earned -3.85M in profits. Earnings per share was -2.76.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -3.77M
- Pretax Income
- -3.85M
- Net Income
- -3.85M
- EBITDA
- -3.63M
- Earnings Per Share (EPS)
- -2.76
Cash Flow
In the last 12 months, operating cash flow was -3.49M and capital expenditures 0, giving a free cash flow of -3.49M billion.
- Operating Cash Flow
- -3.49M
- Free Cash Flow
- -3.49M
- Free Cash Flow per Share
- -2.46
Dividends & Yields
Lakewood-Amedex Biotherapeutics Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -995.56%
- Earnings Yield
- -2587.53%
Stock Price Statistics
- Beta
- -0.22
- 52-Week Price Change
- -99.77%
- 50-Day Moving Average
- 1.38
- 200-Day Moving Average
- 7.13
- Relative Strength Index (RSI)
- 16.56
- Average Volume (3m)
- 2.09M
Financial Position
Lakewood-Amedex Biotherapeutics Inc. as a current ratio of 0.13, with Debt / Equity ratio of -84.52%
- Current Ratio
- 0.13
- Quick Ratio
- 0.13
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- -0.39
- Interest Coverage Ratio
- -37.39
Taxes
In the past 12 months, Lakewood-Amedex Biotherapeutics Inc. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Lakewood-Amedex Biotherapeutics Inc. EV to EBITDA ratio is 0.30, with an EV/FCF ratio of 0.61.
- EV to Sales
- 0.00
- EV to EBITDA
- 0.30
- EV to Free Cash Flow
- 0.61
- EV to Operating Cash Flow
- 0.61
Balance Sheet
Lakewood-Amedex Biotherapeutics Inc. has $4.58M in cash and marketable securities with $101.62K in debt, giving a net cash position of $4.48M billion.
- Cash & Marketable Securities
- $4.58M
- Total Debt
- $101.62K
- Net Cash
- $4.48M
- Net Cash Per Share
- $1.89
- Tangible Book Value Per Share
- $3.05
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Lakewood-Amedex Biotherapeutics Inc. is $3.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $3.00
- Price Target Upside
- 1400.00% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -140.44%
